Cytokinetics R&D Day Spotlights Muscle Programs Beyond Heart Failure Drug
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cytokinetics made headlines with its heart failure drug in May after Amgen elected in to its option on worldwide rights (except in Japan), but its pipeline – presented at an R&D day Sept. 18 – holds other assets that could be strong candidates from the young company. In particular, Cytokinetics’ early stage skeletal muscle candidate garnered excitement from Wall Street for its wider breadth of uses.